Introduction {#s1}
============

Mutations in *RMRP* (mitochondrial RNA-processing endoribonuclease) cause a spectrum of autosomal recessive skeletal dysplasias with variable severity. These are currently classified as cartilage-hair hypoplasia (CHH, MIM \#250250), anauxetic dysplasia-1 (ANXD-1, MIM \#607095) and metaphyseal dysplasia without hypotrichosis (MDWH, MIM \#250460). CHH is the most common presentation and is characterised by metaphyseal chondrodysplasia, hair hypoplasia, variable immunodeficiency and anaemia.[@R1] In addition, patients with CHH have a high risk of cancer often resulting in premature death.[@R3] Clinical manifestations of CHH vary considerably, even among siblings.[@R1]

ANXD represents the most severe end of the *RMRP* skeletal disease spectrum. It is a rare clinical entity with extremely severe short stature---tallest reported patient having a height of 74 cm at 16 years---and can be caused by mutations in *RMRP* (ANXD-1) or POP1 (ANXD-2, MIM \#602486).[@R4] In contrast to the mainly metaphyseal involvement seen in CHH and MDWH, vertebral bodies, pelvis and femoral epiphyses are also affected in ANXD. Apart from mild mental retardation, no extraskeletal manifestations have been reported. The oldest reported individual with ANXD-1 was 16 years old and no data on long-term disease course are available.

MDWH has been described as an isolated skeletal dysplasia in which hair hypoplasia, immunodeficiency and other extraskeletal manifestations are absent.[@R7] Only 11 patients with MDWH have been previously reported, aged 5--11.5 years, and their clinical course beyond childhood is unknown.[@R7]

*RMRP* mutations in CHH, ANXD and MDWH differ and possibly have different biological consequences, explaining distinct clinical presentation. Mutated *RMRP* in ANXD-1 results in normal processing of messenger RNA (mRNA), but impaired ribosomal RNA (rRNA) cleavage, while in CHH mRNA cleavage is also impacted.[@R5] It has been proposed that rRNA and mRNA cleavage activity correlate with the degree of bone dysplasia and immunodeficiency, respectively.[@R11]

Our recent observation of severe bone marrow failure in an adult patient with MDWH-like presentation in childhood and the large variability in disease severity in our CHH cohort[@R2] prompted us to evaluate long-term outcome in patients with *RMRP*-associated skeletal dysplasia who have normal hair and absent extraskeletal manifestations in early childhood.

Methods {#s2}
=======

The index patient with MDWH was recruited to the study after diagnosis of agranulocytosis. The main study cohort involved 80 Finnish patients with genetically confirmed *RMRP*-related skeletal dysplasia, who were initially identified and underwent interview, clinical examination, radiographic assessment and blood sampling in 1985--1991. A follow-up visit was conducted in 2011--2015, when patients were contacted and invited for an interview, clinical assessment and blood tests. We also collected health information for the 80 patients from two Finnish National Medical Databases. The Care Register for Health Care has since 1969 recorded the activities of health centres, hospitals and other institutions providing inpatient or home nursing care. Outpatient primary healthcare data were also derived from the Register of Primary Healthcare Visits, which covers all health centres in Finland since 2011. Database information included health service providers, dates of the visits, diagnoses, as well as diagnostic and therapeutic procedures. Based on database information, we then collected and reviewed all patients' detailed health records for inpatient and outpatient visits. Additionally, data on malignancies were obtained from the Finnish Cancer Register and mortality data from the Statistics Finland.

Birth lengths were compared with normal Finnish population[@R13] and SD scores (SDS), adjusted for gestational age, were used for analysis.

Statistical analysis was performed with IBM SPSS Statistics software V.23. The Fisher's exact test and regression analyses were applied as appropriate.

Results {#s3}
=======

Case report {#s3-1}
-----------

We identified a patient, followed at our institution for skeletal dysplasia with normal hair and absent extraskeletal manifestations. She was born at term measuring 3110 g (−1.0 SDS) and 46 cm (−2.4 SDS). She developed progressive short stature ([figure 1](#F1){ref-type="fig"}), for which growth hormone therapy at 6--7 years of age was ineffective. Skeletal dysplasia was suspected and confirmed at 7 years of age when radiographs revealed skeletal changes consistent with mainly epiphyseal dysplasia, particularly in the hands and hips ([figure 2](#F2){ref-type="fig"}). Very mild metaphyseal changes were also noticed, and they became less apparent with age ([figure 2](#F2){ref-type="fig"}). She underwent several surgeries for leg deformity (valgus in knees, varus in feet) and also developed significant scoliosis. She had beautiful long thick hair ([figure 2](#F2){ref-type="fig"}). In addition to a few episodes of otitis media, her childhood history of infections was remarkable only for severe varicella, molluscum contagiosum and skin warts. She had mild lymphopenia, but no further immunological evaluations were regarded indicated. At 19 years, a skeletal dysplasia gene panel revealed compound heterozygous variants in the *RMRP* gene, n.155G\>T and n.-5delins21 (NCBI reference sequence: NR_003051.3), confirming a *RMRP*-related skeletal dysplasia ([figure 3](#F3){ref-type="fig"}).

![Growth in a patient with *RMRP* mutations, showing a typical pattern of growth failure progressing particularly during the first year of life and during puberty. The patient received growth hormone therapy from 6 to 7 years of age, with no effect on growth.](jmedgenet-2019-106131f01){#F1}

![Photographs and radiographs of the index patient. At 7 years, she had short stature with short limbs, valgus deformity of the knees and long, thick hair (A). Facial features, eye lashes and eye brows were normal (B). Radiographs indicated no metaphyseal irregularity at the wrist or hand (C) or the knee (D), although subtle widening of the metaphyseal area was observed in the distal femur and proximal tibia. Epiphyses in the hand (C) and knee (D) were small and flat. The patient developed significant scoliosis (E). Small and flat epiphyses were also seen at the hip (F) and by adulthood the femoral necks were short and the proximal femurs deformed (G).](jmedgenet-2019-106131f02){#F2}

![Sanger ECG of two different regions of the *RMRP* gene demonstrating (arrows) variants in the index patient and her parents.](jmedgenet-2019-106131f03){#F3}

Evaluation for fatigue at 18 years after an episode of rhinosinusitis and conjunctivitis uncovered pancytopenia (haemoglobin 93 g/L (normal range 117--155), platelets 109×10^9^/L (normal range 150--360), white cell count 1.2×10^9^/L (normal range 3.4--8.2) and no detectable neutrophils. While anaemia and thrombocytopenia were mild and did not require therapy, agranulocytosis persisted. The patient was lymphopenic (0.7×10^9^/L (normal range 1.3--3.6), however, immunoglobulin levels appeared normal. Bone marrow examination revealed normal age-correlated cellularity (70%) but absent granulopoiesis and remarkable over-representation of lymphocytes (93% CD3+ cells, of which 60% were also CD8+). There was no clonal expansion of T cell receptor γ chain gene and the findings were not consistent with malignancy.

During the following year, agranulocytosis persisted despite treatment with filgrastim or prednisolone and the patient required multiple hospitalisations for bacterial and viral infections. She, therefore, received a haematopoietic stem cell transplant (HSCT) from a human leukocyte antigen (HLA) -identical unrelated donor after a reduced-toxicity conditioning with treosulfan, fludarabine and antithymocyte globulin. Neutrophils engrafted on day 20 post-HSCT, and bone marrow showed normal cellularity and total donor chimerism 2 months post-HSCT. She continued to experience viral and bacterial infections and was diagnosed with sinusoid obstruction syndrome 7 months post-transplant. Despite normal bone marrow cellularity and full chimerism, her peripheral blood cell counts remain below normal limits at 11 months after HSCT, which potentially stems from multifactorial aetiology.

Cohort of CHH patients with normal hair {#s3-2}
---------------------------------------

In the cohort of 80 patients with confirmed biallelic *RMRP* mutations, we identified 10 subjects fulfilling the criteria for MDWH: in the preschool age, they presented with metaphyseal dysplasia, normal hair and absent extraskeletal manifestations ([table 1](#T1){ref-type="table"}). The remaining 70 patients had a clinical presentation typical for CHH. When clinical symptoms, radiographic features and laboratory results were compared, the 10 patients with MDWH did not differ significantly from the rest of the cohort, except for birth length. Their mean birth length was −2.03 SDS (95% CI −1.09 to −2.98 SDS), compared with the rest of the cohort with mean length of −3.06 SDS (95% CI −2.97 to −3.03 SDS) (p=0.031, B coefficient=0.647).

###### 

Clinical, laboratory and outcome characteristics of 10 patients fulfilling the criteria of metaphyseal dysplasia without hypotrichosis in early childhood

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    P 1                                        P 2                            P 3                P 4                                                                 P 5                                             P 6                                                P 7                                                   P 8                                        P 9                                                      P 10
  ------------------------------------------------- ------------------------------------------ ------------------------------ ------------------ ------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------- ----------------------------------------------------- ------------------------------------------ -------------------------------------------------------- ----------------------------------------------------------------------
  Mutation\*                                        n.71A\>G/\                                 n.71A\>G/\                     n.71A\>G/\         n.71A\>G/\                                                          n.71A\>G/\                                      n.71A\>G/\                                         n.71A\>G/\                                            n.71A\>G/\                                 n.71A\>G/\                                               n.71A\>G/\
                                                    71A\>G                                     263G\>T                        71A\>G             263G\>T                                                             71A\>G                                          263G\>T                                            71A\>G                                                71A\>G                                     71A\>G                                                   71A\>G

  Age at recruitment, years                         4.3                                        0.6                            6.6                10.2                                                                14.2                                            15.3                                               17.1                                                  26.4                                       23.8                                                     34.3

  Age at the latest follow-up, years                20.9                                       28.9                           34.8               37.6                                                                44.9                                            46.3                                               48.1                                                  50.8                                       54.6                                                     65.4

  Duration of follow-up, years                      16.6                                       28.3                           28.2               27.4                                                                30.7                                            31.0                                               31.0                                                  24.4                                       30.8                                                     31.1

  Age at the first extraskeletal manifestation      20.7                                       N/A                            N/A                7--17                                                               7--17                                           9                                                  Adulthood                                             50.5                                       7--17                                                    43.3

  First extraskeletal manifestation                 Hodgkin disease                            Pollen allergy                 Pollen allergy     Recurrent Sin                                                       Recurrent Sin requiring sinus puncture          Recurrent Sin requiring sinus surgery at 8 years   Recurrent Sin requiring sinus punctures at 37 years   Neuroendocrine carcinoma                   Recurrent Sin with polyposis requiring sinus punctures   Recurrent Sin, requiring sinus surgery at 61 years

  Other extraskeletal manifestations in adulthood   None                                       None                           None               Recurrent otitis media since 31 years, skin warts, pollen allergy   Pollen allergy, bronchiectasis since 43 years   Pollen allergy                                     Skin warts                                            Pollen allergy                             Maxillary polyposis requiring polypectomy at 14 years    Recurrent pneumonia since 55 years and bronchiectasis since 60 years

  Severity of growth failure†                       Severe                                     Mild                           Mild               Moderate                                                            Mild                                            Mild                                               Mild                                                  Mild                                       Moderate                                                 Mild

  Adult height group, cm                            120--130                                   130--140                       130--140           130--140                                                            130--140                                        140--150                                           130--140                                              130--140                                   120--130                                                 120--130

  Lymphocyte subtypes‡                              N/A                                        Low CD19+at 0.6 and 26 years   Normal             Normal                                                              Normal                                          Low CD3+ and CD4+ at 44 years                      Normal                                                N/A                                        Low CD3+, CD4+ and CD8+ at 36 and 52 years               Normal

  Lymphocyte proliferation§                         N/A                                        Abnormal at 0.6 years          Normal             Abnormal at 10 years                                                N/A                                             Abnormal at 2 years                                Abnormal at 7 years                                   Abnormal at 12 years                       Abnormal at 10 years                                     N/A

  IgA, M and G levels¶                              N/A                                        Normal                         Normal             Normal                                                              Normal                                          Normal                                             Normal                                                Normal                                     Normal                                                   Normal IgA and IgG, low IgM at 60 years

  SAD\*\*                                           N/A                                        N/A                            Yes, at 32 years   N/A                                                                 N/A                                             None at 44 years                                   None at 45 years                                      N/A                                        Yes, at 52 years                                         None at 62 years

  Outcome                                           Died at 20 years during cancer treatment   Alive                          Alive              Alive                                                               Alive                                           Alive                                              Alive                                                 Died at 50 years during cancer treatment   Alive                                                    Alive
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Reference sequence: NR_003051.3.

†Growth failure classified based on CHH-specific growth charts as described in.[@R20]

‡Lymphocyte subtypes included CD3+, CD4+, CD8+, CD19+ and CD16/56+ absolute cell numbers measured by flow cytometry as described in.[@R2]

§Lymphocyte proliferation measured to PHA, ConA and PWM as described in.[@R20]

¶Measured as described in.[@R2]

\*\*Specific antibody deficiency was defined as inadequate antibody response to Pneumovax: a fourfold rise in antibody titres and post-immunisation antibody levels ≥0.35 µg/mL to \<70% of serotypes, measured as described previously in.[@R2]

CHH, cartilage-hair hypoplasia; NA, not available; PHA, phytohaemagglutinin; SAD, specific antibody deficiency.

Among the 10 patients with MDWH, we identified eight patients who despite skeletal-only presentation during childhood, later developed extraskeletal manifestations ([table 1](#T1){ref-type="table"}). Their clinical course was unremarkable except for short-stature until the first extraskeletal symptoms at 7--17, 20, 43 and even 50 years of age. Two patients developed malignancy (Hodgkin lymphoma and neuroendocrine carcinoma), and both deceased during chemotherapy. Another six patients developed signs of immunodeficiency including recurrent episodes of otitis media, rhinosinusitis and pneumonia, as well as bronchiectasis.

Two patients with MDWH are alive and well at 28 and 34 years, with no extraskeletal manifestations apart from pollen allergy. One of them has been diagnosed with asymptomatic specific antibody deficiency, another has low levels of peripheral B cells ([table 1](#T1){ref-type="table"}).

Systematic laboratory assessments of immunological parameters prior to the onset of extraskeletal manifestations have not been performed outside research visits, reflecting mild initial clinical course of the patients. Abnormal lymphocyte proliferative responses were detected in four patients before the development of clinical immunodeficiency and malignancy.

Discussion {#s4}
==========

We tested our hypothesis that MDWH is not a separate disease entity by exploring the long-term outcome data in a large cohort on patients with *RMRP* mutations and skeletal dysplasia and demonstrated that subjects with MDWH can indeed develop late-onset immunodeficiency and malignancy, characteristic for CHH. Our index patient with biallelic *RMRP* mutations, skeletal dysplasia, normal hair and largely absent extraskeletal manifestations in childhood, who developed severe bone marrow failure by early adulthood confirms the variable course and the importance of long-term surveillance.

We describe 10 Finnish patients from our large (n=80) CHH cohort who first presented with skeletal dysplasia only, thus fulfilling the criteria for MDWH. However, eight of them developed malignancy or clinical immunodeficiency later during follow-up. Thus, we suggest that MDWH represents cases of CHH with a risk for late-onset extraskeletal symptoms.

The 10 patients with MDWH presentation differed from the rest of the CHH cohort only by a less profound growth failure at birth. Although it would be tempting to associate milder growth failure with less severe extraskeletal manifestations, our present and previous studies contradict this by describing severe and even fatal complications of immunodeficiency in some patients with very mild growth failure.[@R12]

Genotype-phenotype correlations in cases with *RMRP* mutations remain poorly understood.[@R11] Possible explanations include polymorphisms in *RMRP* gene and non-allelic modifiers.[@R11] Almost all patients in our cohort were homozygous or heterozygous for the founder n.71A\>G mutation. However, the patient with agranulocytosis was compound heterozygous for two very rare *RMRP* mutations n.155G\>T and n.-5delins21. The n.155G\>T has previously been identified in compound heterozygous state with the founder mutation n.71G\>A in a Finnish CHH patient.[@R15] In addition, another variant in the same position, n.155G\>C has been found in compound heterozygous state with a 15 bp duplication at position −24 in the promoter region in a patient with CHH, Omenn syndrome and CD8 lymphopenia.[@R16] Regarding the other mutation, almost the same insertion, differing from the identified variant only by two nucleotides, is a 20 bp duplication, n.-6\_−25dup20 (n.5\_−24dup20 using NR_003051.3 transcript), described by Hermanns *et al*.[@R17] The *RMRP* variant n.-6\_−25dup20 was found in two Belgian CHH patients (siblings, identical mutations) in compound heterozygous state with both, n.91G\>A and n.101C\>T (n.92G\>A and n.102C\>T according to NR_003051.3) with unexplained functional implication. Both patients had clinical diagnosis of CHH. The n.-6\_−25dup20 duplication leads to reduced (but not absent) activity of the *RMRP* promoter compared with the wild type promoter, suggesting that *RMRP* transcription is decreased but not abolished.[@R18]

The spectrum of diseases caused by *RMRP* mutations incorporates skeletal dysplasia of various severity and diverse extraskeletal manifestations. Clinical classification into MDWH, CHH and ANXD is based on the degree of skeletal dysplasia, the presence of hair hypoplasia and other extraskeletal manifestations. However, no long-term follow-up data have until now been published for patients with *RMRP* mutations. Therefore, it has been unclear, whether MDWH or ANXD patients develop clinically significant immunodeficiency or malignancies later in life. Our index patient had skeletal characteristics overlapping with ANXD (significant hip and spine involvement) and the findings were not typical for CHH or MDWH. In contrast, the patients with MDWH presented with radiographic findings typical for CHH.[@R19]

Patients with CHH present with extremely variable clinical features, and even short-stature can be absent in childhood.[@R11] In the largest clinical series of 108 individuals with CHH, hair was normal in 7% and no susceptibility to infections could be shown in 44% of the patients.[@R1] Thus, some of the patients could be designated to have MDWH. On the other hand, severe growth failure up to −11 SD that is in the range of ANXD has also been reported in subjects with CHH,[@R1] raising the question of whether MDWH, CHH and ANXD are actually all the same disease of variable severity.

Labelling mildly affected patients with *RMRP* mutations as having MDWH can negatively affect the management and follow-up of such patients, blunting the clinicians away from potential extraskeletal complications. Our study demonstrates the development of clinically significant immunodeficiency and malignancies in previously asymptomatic short-statured patients. Therefore, careful and regular clinical assessment should be organised for individuals with *RMRP* mutations even in the absence of extraskeletal manifestations on presentation.

We demonstrate serious late-onset extraskeletal manifestations in patients with MDWH and suggest that these cases should be reclassified and managed as CHH.
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